Article | Published:

MAGE-A expression in oral and laryngeal leukoplakia predicts malignant transformation


Leukoplakia is a potential precursor of oral as well as laryngeal squamous cell carcinoma. Risk assessment of malignant transformation based on the grade of dysplasia of leukoplakia often does not lead to reliable results. However, oral squamous cell carcinoma, laryngeal squamous cell carcinoma, and leukoplakia express single or multiple members of the melanoma-associated antigens A (MAGE-A) family, while MAGE-A are absent in healthy mucosal tissue. The present study aimed at determining if there is an association between the expression of MAGE-A in leukoplakia and malignant transformation to oral or laryngeal squamous cell carcinoma. Paraffin-embedded tissues of 205 oral and laryngeal leukoplakia, 90 corresponding tumors, and 40 healthy oral mucosal samples were included in the study. The grade of dysplasia of the leukoplakia samples was determined histopathologically. The leukoplakia samples were divided into lesions that transformed to oral and laryngeal squamous cell carcinoma (n = 91) and lesions that did not (n = 114) during a 5 years follow-up. The expression of MAGE-A3/6 and MAGE-A4 was analyzed by real-time RT-PCR. The expression of MAGE-A 1–4, 6, and 12 was determined by immunohistochemistry. A total of 59.3% of the transforming leukoplakia expressed at least one of the examined antigens as opposed to an expression rate of 3.5% of all non-transforming leukoplakia. There was no MAGE-A expression in healthy oral mucosa. The risk of malignant transformation was statistically significantly associated with MAGE-A expression in immunohistochemistry (p < 0.001) and real-time RT-PCR (MAGE-A3/6, p = 0.001; MAGE-A4, p = 0.002) analyses. There was no significant association between MAGE-A expression and the grade of dysplasia (“low-grade”, D0/D1; “high-grade”, D2/D3) in immunohistochemistry (p = 0.412) and real-time RT-PCR (MAGE-A3/6, p = 0.667; MAGE-A4, p = 0.756). It seems that the analysis of the MAGE-A expression profile may support the identification of leukoplakia at risk for malignant transformation. Therefore, efforts should be made to establish this analysis as a routine procedure in addition to conventional histopathology.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


  1. 1.

    Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–386.

  2. 2.

    Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2018. CA Cancer J Clin. 2018;68:7–30.

  3. 3.

    Sundermann BV, Uhlmann L, Hoffmann J, Freier K, Thiele OC.The localization and risk factors of squamous cell carcinoma in the oral cavity: A retrospective study of 1501 cases.J Cranimaxillofac Surg. 2018;46:177–82.

  4. 4.

    Ong TK, Murphy C, Smith AB, et al. Survival after surgery for oral cancer: a 30-year experience. Br J Oral Maxillofac Surg. 2017;55:911–6.

  5. 5.

    Tribius S, Donner J, Pazdyka H, et al. Survival and overall treatment time after postoperative radio(chemo)therapy in patients with head and neck cancer. Head Neck. 2016;38:1058–65.

  6. 6.

    Jansen L, Buttmann-Schweiger N, Listl S, et al. Differences in incidence and survival of oral cavity and pharyngeal cancers between Germany and the United States depend on the HPV-association of the cancer site. Oral Oncol. 2018;76:8–15.

  7. 7.

    Kuribayashi Y, Tsushima F, Morita KI, et al. Long-term outcome of non-surgical treatment in patients with oral leukoplakia. Oral Oncol. 2015;51:1020–5.

  8. 8.

    Isenberg JS, Crozier DL, Dailey SH. Institutional and comprehensive review of laryngeal leukoplakia. Ann Otol Rhinol Laryngol. 2008;117:74–79.

  9. 9.

    Warnakulasuriya S, Ariyawardana A. Malignant transformation of oral leukoplakia: a systematic review of observational studies. J Oral Pathol Med. 2016;45:155–66.

  10. 10.

    van Hulst AM, Kroon W, van der Linden ES, et al. Grade of dysplasia and malignant transformation in adults with premalignant laryngeal lesions. Head Neck. 2016;38:2284–90.

  11. 11.

    Scheifele C, Reichart PA. Oral leukoplakia in manifest squamous epithelial carcinoma. A clinical prospective study of 101 patients. Mund Kiefer Gesichtschir. 1998;2:326–30.

  12. 12.

    Reibel J. Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics. Crit Rev Oral Biol Med. 2003;14:47–62.

  13. 13.

    Weller MD, Nankivell PC, McConkey C, et al. The risk and interval to malignancy of patients with laryngeal dysplasia; a systematic review of case series and meta-analysis. Clin Otolaryngol. 2010;35:364–72.

  14. 14.

    Silverman S Jr., Gorsky M, Lozada F. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer. 1984;53:563–8.

  15. 15.

    Johnson NW, Jayasekara P, Amarasinghe AA. Squamous cell carcinoma and precursor lesions of the oral cavity: epidemiology and aetiology. Periodontol 2000. 2011;57:19–37.

  16. 16.

    Speight PM, Khurram SA, Kujan O. Oral potentially malignant disorders: risk of progression to malignancy. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;125:612–27.

  17. 17.

    Warnakulasuriya S, Johnson NW, van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med. 2007;36:575–80.

  18. 18.

    Krishnan L, Karpagaselvi K, Kumarswamy J, et al. A. Inter- and intra-observer variability in three grading systems for oral epithelial dysplasia. J Oralmaxillofac Pathol. 2016;20:261–8.

  19. 19.

    Speight PM, Abram TJ, Floriano PN, et al. Interobserver agreement in dysplasia grading: toward an enhanced gold standard for clinical pathology trials. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;120:474–82.

  20. 20.

    Pitiyage G, Tilakaratne WM, Tavassoli M, et al. Molecular markers in oral epithelial dysplasia: review. J Oral Pathol Med. 2009;38:737–52.

  21. 21.

    Rivera C, Oliveira AK, Costa RAP, et al. Prognostic biomarkers in oral squamous cell carcinoma: a systematic review. Oral Oncol. 2017;72:38–47.

  22. 22.

    Ries J, Agaimy A, Vairaktaris E, et al. Evaluation of MAGE-A expression and grade of dysplasia for predicting malignant progression of oral leukoplakia. Int J Oncol. 2012;41:1085–93.

  23. 23.

    Ries J, Agaimy A, Vairaktaris E, et al. Detection of MAGE-A expression predicts malignant transformation of oral leukoplakia. Cancer Invest. 2012;30:495–502.

  24. 24.

    Nankivell P, Weller M, McConkey C, et al. Biomarkers in laryngeal dysplasia: a systematic review. Head Neck. 2011;33:1170–6.

  25. 25.

    Pereira CM, Gomes CC, De Fatima Correia Silva J, et al. Evaluation of MAGE A1 in oral squamous cell carcinoma. Oncol Rep. 2012;27:1843–8.

  26. 26.

    Ries J, Schultze-Mosgau S, Neukam F, et al. Investigation of the expression of melanoma antigen-encoding genes (MAGE-A1 to -A6) in oral squamous cell carcinomas to determine potential targets for gene-based cancer immunotherapy. Int J Oncol. 2005;26:817–24.

  27. 27.

    Mollaoglu N, Vairaktaris E, Nkenke E, et al. Expression of MAGE-A12 in oral squamous cell carcinoma. Dis Markers. 2008;24:27–32.

  28. 28.

    Muller-Richter UD, Dowejko A, Peters S, et al. MAGE-A antigens in patients with primary oral squamous cell carcinoma. Clin Oral Investig. 2010;14:291–6.

  29. 29.

    Han L, Jiang B, Wu H, et al. Expression and prognostic value of MAGE-A9 in laryngeal squamous cell carcinoma. Int Clin Exp Pathol. 2014;7:6734–42.

  30. 30.

    Liu S, Sang M, Xu Y, et al. Expression of MAGE-A1, -A9, -A11 in laryngeal squamous cell carcinoma and their prognostic significance: a retrospective clinical study. Acta Otolaryngol. 2016;136:506–13.

  31. 31.

    Ries J, Vairaktaris E, Mollaoglu N, et al. Expression of melanoma-associated antigens in oral squamous cell carcinoma. J Oral Pathol Med. 2008;37:88–93.

  32. 32.

    Figueiredo DL, Mamede RC, Spagnoli GC, et al. High expression of cancer testis antigens MAGE-A, MAGE-C1/CT7, MAGE-C2/CT10, NY-ESO-1, and gage in advanced squamous cell carcinoma of the larynx. Head Neck. 2011;33:702–7.

  33. 33.

    Krauss E, Rauthe S, Gattenlohner S, et al. MAGE-A antigens in lesions of the oral mucosa. Clin Oral Investig. 2011;15:315–20.

  34. 34.

    Ries J, Mollaoglu N, Toyoshima T, et al. A novel multiple-marker method for the early diagnosis of oral squamous cell carcinoma. Dis Markers. 2009;27:75–84.

  35. 35.

    Gillenwater AM, Vigneswaran N, Fatani H, et al. Proliferative verrucous leukoplakia (PVL): a review of an elusive pathologic entity! Adv Anat Pathol. 2013;20:416–23.

  36. 36.

    Patel SG, Shah JP. TNM staging of cancers of the head and neck: striving for uniformity among diversity. CA Cancer J Clin. 2005;55:242–58.

  37. 37.

    Paleri V, Mehanna H, Wight RG. TNM classification of malignant tumours7th edition: what’s new for head and neck? Clin Otolaryngol. 2010;35:270–2.

  38. 38.

    Warnakulasuriya S, Reibel J, Bouquot J, et al. Oral epithelial dysplasia classification systems: predictive value, utility, weaknesses and scope for improvement. J Oral Pathol Med. 2008;37:127–33.

  39. 39.

    Karatayli-Ozgursoy S, Pacheco-Lopez P, Hillel AT, et al. Laryngeal dysplasia, demographics, and treatment: a single-institution, 20-year review. JAMA Otolaryngol Head Neck Surg. 2015;141:313–8.

  40. 40.

    Solomon MC, Vidyasagar MS, Fernandes D, et al. The prognostic implication of the expression of EGFR, p53, cyclin D1, Bcl-2 and p16 in primary locally advanced oral squamous cell carcinoma cases: a tissue microarray study. Med Oncol. 2016;33:138.

  41. 41.

    Ries J, Vairaktaris E, Agaimy A, et al. The relevance of EGFR overexpression for the prediction of the malignant transformation of oral leukoplakia. Oncol Rep. 2013;30:1149–56.

  42. 42.

    Hartmann S, Kipke RU, Rauthe S, et al. Oral brush biopsy and melanoma-associated antigens A (MAGE-A) staining in clinically suspicious lesions. J Craniomaxillofac Surg. 2015;43:2214–8.

  43. 43.

    Hartmann S, Kriegebaum U, Kuchler N, et al. Correlation of MAGE-A tumor antigens and the efficacy of various chemotherapeutic agents in head and neck carcinoma cells. Clin Oral Investig. 2014;18:189–97.

  44. 44.

    Abadie WM, Partington EJ, Fowler CB, et al. Optimal management of proliferative verrucous leukoplakia: a systematic review of the literature. Otolaryngol Head Neck Surg. 2015;153:504–11.

  45. 45.

    Ribeiro AS, Salles PR, da Silva TA, et al. A review of the nonsurgical treatment of oral leukoplakia. Int J Dent. 2010;2010:186018.

  46. 46.

    Cloitre A, Rosa RW, Arrive E, et al. Outcome of CO2 laser vaporization for oral potentially malignant disorders treatment. Med Oral Pathol Oral Cir Bucal. 2018;23:237–47.

  47. 47.

    Mogedas-Vegara A, Hueto-Madrid JA, Chimenos-Kustner E, et al. Oral leukoplakia treatment with the carbon dioxide laser: a systematic review of the literature. J Cranimaxillofac Surg. 2016;44:331–6.

  48. 48.

    Kumar A, Cascarini L, McCaul JA, et al. How should we manage oral leukoplakia? Br J Oral Maxillofac Surg. 2013;51:377–83.

  49. 49.

    van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. Oral Oncol. 2009;45:317–23.

  50. 50.

    Sang M, Lian Y, Zhou X, et al. MAGE-A family: attractive targets for cancer immunotherapy. Vaccine. 2011;29:8496–8500.

  51. 51.

    Lee AK, Potts PR. A comprehensive guide to the MAGE Family of ubiquitin ligases. J Mol Biol. 2017;429:1114–42.

Download references


All authors have read the manuscript and approved its submission. The present work was performed in (partial) fulfillment of the requirements for obtaining the degree “Dr. med. dent.” at the Friedrich-Alexander-University Erlangen-Nürnberg (FAU). The authors thank the research technicians Mrs. E. Diebel and Mrs. S. Schönherr for the valuable support in assistance and performance in immunohistochemistry and Mrs. A. Krautheim-Zenk for the valuable support in assistance and performance in RNA isolation and RT-qPCR analyses.

Author information

Conflict of interest

The authors declare that they have no conflict of interest.

Correspondence to Christoph A. Baran.

Supplementary information

  1. Supplementary data 1

  2. Supplemetary data 2

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark
Fig. 1
Fig. 2
Fig. 3
Fig. 4